vs
CF BANKSHARES INC.（CFBK）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是CF BANKSHARES INC.的1.9倍（$30.3M vs $15.7M），CF BANKSHARES INC.净利率更高（40.0% vs -221.3%，领先261.4%），REGENXBIO Inc.同比增速更快（43.0% vs 12.6%），CF BANKSHARES INC.自由现金流更多（$18.2M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 13.7%）
CF BANKSHARES INC.是一家美国区域性银行控股企业，通过旗下社区银行子公司运营，提供全方位个人及商业银行解决方案，包括存款产品、各类贷款、财富管理服务及数字银行工具，主要服务美国中西部地区的个人消费者和中小企客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CFBK vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.9倍
$15.7M
营收增速更快
RGNX
高出30.4%
12.6%
净利率更高
CFBK
高出261.4%
-221.3%
自由现金流更多
CFBK
多$71.0M
$-52.8M
两年增速更快
RGNX
近两年复合增速
13.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $15.7M | $30.3M |
| 净利润 | $5.7M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 43.4% | -190.0% |
| 净利率 | 40.0% | -221.3% |
| 营收同比 | 12.6% | 43.0% |
| 净利润同比 | 29.9% | -31.2% |
| 每股收益（稀释后） | $0.88 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CFBKRGNX
| Q4 25 | $15.7M | $30.3M | ||
| Q3 25 | $15.5M | $29.7M | ||
| Q2 25 | $15.6M | $21.4M | ||
| Q1 25 | $14.1M | $89.0M | ||
| Q4 24 | $14.0M | $21.2M | ||
| Q3 24 | $13.1M | $24.2M | ||
| Q2 24 | $12.6M | $22.3M | ||
| Q1 24 | $12.2M | $15.6M |
净利润CFBKRGNX
| Q4 25 | $5.7M | $-67.1M | ||
| Q3 25 | $2.3M | $-61.9M | ||
| Q2 25 | $5.0M | $-70.9M | ||
| Q1 25 | $4.4M | $6.1M | ||
| Q4 24 | $4.4M | $-51.2M | ||
| Q3 24 | $4.2M | $-59.6M | ||
| Q2 24 | $1.7M | $-53.0M | ||
| Q1 24 | $3.1M | $-63.3M |
毛利率CFBKRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CFBKRGNX
| Q4 25 | 43.4% | -190.0% | ||
| Q3 25 | 17.5% | -176.3% | ||
| Q2 25 | 41.1% | -296.3% | ||
| Q1 25 | 39.5% | 13.6% | ||
| Q4 24 | 36.9% | -242.1% | ||
| Q3 24 | 40.4% | -256.6% | ||
| Q2 24 | 15.4% | -251.3% | ||
| Q1 24 | 30.9% | -408.8% |
净利率CFBKRGNX
| Q4 25 | 40.0% | -221.3% | ||
| Q3 25 | 15.1% | -208.3% | ||
| Q2 25 | 32.3% | -331.8% | ||
| Q1 25 | 31.4% | 6.8% | ||
| Q4 24 | 35.2% | -241.3% | ||
| Q3 24 | 32.2% | -246.3% | ||
| Q2 24 | 13.5% | -237.7% | ||
| Q1 24 | 25.2% | -405.4% |
每股收益（稀释后）CFBKRGNX
| Q4 25 | $0.88 | $-1.30 | ||
| Q3 25 | $0.36 | $-1.20 | ||
| Q2 25 | $0.77 | $-1.38 | ||
| Q1 25 | $0.68 | $0.12 | ||
| Q4 24 | $0.68 | $-0.99 | ||
| Q3 24 | $0.65 | $-1.17 | ||
| Q2 24 | $0.26 | $-1.05 | ||
| Q1 24 | $0.47 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $184.4M | $102.7M |
| 总资产 | $2.1B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CFBKRGNX
| Q4 25 | $259.0M | $230.1M | ||
| Q3 25 | $272.4M | $274.2M | ||
| Q2 25 | $275.7M | $323.3M | ||
| Q1 25 | $241.0M | $267.9M | ||
| Q4 24 | $235.3M | $234.7M | ||
| Q3 24 | $233.5M | $255.5M | ||
| Q2 24 | $241.8M | $290.4M | ||
| Q1 24 | $236.9M | $338.7M |
股东权益CFBKRGNX
| Q4 25 | $184.4M | $102.7M | ||
| Q3 25 | $179.3M | $161.5M | ||
| Q2 25 | $177.0M | $213.7M | ||
| Q1 25 | $172.7M | $274.2M | ||
| Q4 24 | $168.4M | $259.7M | ||
| Q3 24 | $164.0M | $301.4M | ||
| Q2 24 | $159.6M | $348.3M | ||
| Q1 24 | $158.0M | $390.7M |
总资产CFBKRGNX
| Q4 25 | $2.1B | $453.0M | ||
| Q3 25 | $2.1B | $525.2M | ||
| Q2 25 | $2.1B | $581.0M | ||
| Q1 25 | $2.1B | $490.9M | ||
| Q4 24 | $2.1B | $466.0M | ||
| Q3 24 | $2.1B | $519.1M | ||
| Q2 24 | $2.0B | $569.4M | ||
| Q1 24 | $2.0B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $18.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | 115.6% | -174.0% |
| 资本支出强度资本支出/营收 | 3.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.26× | — |
| 过去12个月自由现金流最近4个季度 | $33.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CFBKRGNX
| Q4 25 | $18.7M | $-52.3M | ||
| Q3 25 | $5.5M | $-56.0M | ||
| Q2 25 | $8.0M | $-49.3M | ||
| Q1 25 | $2.2M | $33.6M | ||
| Q4 24 | $14.2M | $-31.6M | ||
| Q3 24 | $-1.3M | $-40.5M | ||
| Q2 24 | $4.0M | $-45.5M | ||
| Q1 24 | $-1.2M | $-55.5M |
自由现金流CFBKRGNX
| Q4 25 | $18.2M | $-52.8M | ||
| Q3 25 | $5.2M | $-56.5M | ||
| Q2 25 | $7.8M | $-49.7M | ||
| Q1 25 | $2.2M | $32.6M | ||
| Q4 24 | $13.9M | $-32.7M | ||
| Q3 24 | $-1.3M | $-40.9M | ||
| Q2 24 | $4.0M | $-46.0M | ||
| Q1 24 | $-1.2M | $-56.0M |
自由现金流率CFBKRGNX
| Q4 25 | 115.6% | -174.0% | ||
| Q3 25 | 33.6% | -189.9% | ||
| Q2 25 | 50.3% | -232.8% | ||
| Q1 25 | 15.2% | 36.6% | ||
| Q4 24 | 99.6% | -154.2% | ||
| Q3 24 | -9.9% | -168.9% | ||
| Q2 24 | 31.6% | -206.2% | ||
| Q1 24 | -9.5% | -358.5% |
资本支出强度CFBKRGNX
| Q4 25 | 3.1% | 1.7% | ||
| Q3 25 | 1.7% | 1.7% | ||
| Q2 25 | 0.7% | 1.8% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 1.9% | 5.1% | ||
| Q3 24 | 0.2% | 1.3% | ||
| Q2 24 | 0.1% | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率CFBKRGNX
| Q4 25 | 3.26× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 0.50× | 5.53× | ||
| Q4 24 | 3.21× | — | ||
| Q3 24 | -0.30× | — | ||
| Q2 24 | 2.35× | — | ||
| Q1 24 | -0.38× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CFBK
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
